Clinical trial · Observational
Impact of CASP3 Gene in Chemoresistance
The Impact of CASP3 Gene in Chemoresistant Breast Cancer
NCT06195371CI-TRIAL-00074442not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. This study aims to evaluate the abnormalities of CASP3 gene in chemo resistance in breast cancer by FISH technique. evaluate the abnormalities of CASP3 gene in chemo resistance in breast cancer by FISH technique. 2. Detect CASP3 gene abnormality relation to survival, chemoresponse \& chemoresistance. 3. Correlate CASP3 gene abnormalities with available clinicopathological data of breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- - Evaluation of casp3 gene abnormalities by fluorescence in situ hybridization in patients with breast cancer
- timeFrame
- baseline
- description
- Evaluation of casp3 gene abnormalities by fluorescence in situ hybridization in patients with breast cancer
Secondary outcomes (1)
- measure
- - correlation between casp3 gene and response to Chemotherapy.
- timeFrame
- baseline
- description
- correlation between casp3 gene and response to Chemotherapy.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 15 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed patients of breast cancer admitted to South Egypt Cancer Institute at different stages of the disease Exclusion Criteria: * Other malignant diseases-Male breast cancer .
References
Publications (7)
- BACKGROUNDFu W, Song J, Li H. Breviscapine reverses doxorubicin resistance in breast cancer and its related mechanisms. Thorac Cancer. 2023 Sep;14(27):2785-2792. doi: 10.1111/1759-7714.15072. Epub 2023 Aug 16. PMID 37584258
- BACKGROUNDWilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID 34905391
- BACKGROUNDXu F, Xia T, Xu QT, Zhang X, Huang YZ, Sun X, Shi L, Zhou XJ, Wei JF, Ding Q. RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression. Int J Biol Sci. 2022 Feb 7;18(4):1724-1736. doi: 10.7150/ijbs.66480. eCollection 2022. PMID 35280673
- BACKGROUNDYaghoubi A, Ghojazadeh M, Abolhasani S, Alikhah H, Khaki-Khatibi F. Correlation of Serum Levels of Vitronectin, Malondialdehyde and Hs- CRP With Disease Severity in Coronary Artery Disease. J Cardiovasc Thorac Res. 2015;7(3):113-7. doi: 10.15171/jcvtr.2015.24. PMID 26430499
- BACKGROUNDAsadi M, Taghizadeh S, Kaviani E, Vakili O, Taheri-Anganeh M, Tahamtan M, Savardashtaki A. Caspase-3: Structure, function, and biotechnological aspects. Biotechnol Appl Biochem. 2022 Aug;69(4):1633-1645. doi: 10.1002/bab.2233. Epub 2021 Aug 22. PMID 34342377
- BACKGROUNDJakubowska K, Guzinska-Ustymowicz K, Famulski W, Cepowicz D, Jagodzinska D, Pryczynicz A. Reduced expression of caspase-8 and cleaved caspase-3 in pancreatic ductal adenocarcinoma cells. Oncol Lett. 2016 Mar;11(3):1879-1884. doi: 10.3892/ol.2016.4125. Epub 2016 Jan 19. PMID 26998093
- BACKGROUNDShalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ. 2015 Apr;22(4):526-39. doi: 10.1038/cdd.2014.216. Epub 2014 Dec 19. PMID 25526085